

REMARKS

Claims 1-5 were pending in the application. Claims 1, 3 and 4 have been amended. In addition, the specification and Abstract have been amended to comply with 37 C.F.R. §1.821. No new matter has been added. Accordingly, claims 1-5 will remain pending in the application upon entry of the instant amendments.

The instant Communication indicates that the above-referenced application fails to comply with the requirements of 37 C.F.R. §§1.821 through 1.825 because a copy of the Sequence Listing in computer readable form has not been submitted to the Patent Office. In addition, the Communication indicates that Figure 1 and at pages 18, 24, 26, 27, 30, 31, 33, 34, 37, 41, 43, 46, 49, 51, 52, 55, 61, and 62 of the specification contain nucleotide and/or amino acid sequences which are encompassed by the Sequence Rules and which are not included in the Sequence Listing. Therefore, the Communication requires the submission of an initial computer readable form (CRF) of the Sequence Listing, a substitute paper (hard) copy of the Sequence Listing, an amendment directing entry of the substitute Sequence Listing into the specification, a statement required by 37 C.F.R. §§1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.821(d), and an amendment to the specification with appropriate notation for sequence identifiers.

Accordingly, Applicants transmit concurrently herewith an initial computer-readable form of the Sequence Listing, a hard (paper) copy of the substitute Sequence Listing, pages 92-183, for the above-referenced application. The specification has been amended to insert the substitute Sequence Listing, and Applicants respectfully request that the pages of the claims and Abstract be renumbered accordingly. The nucleotide and/or amino acid sequences disclosed in Figure 1 and at pages 18, 24, 26, 27, 30, 31, 33, 34, 37, 41, 43, 46, 49, 51, 52, 55, 61, and 62, in addition to page 15 for the DNA-RNA chimeric oligonucleotide, of the specification are now contained in the substitute Sequence Listing. The foregoing pages of the specification have been amended to insert

the specific sequence identifiers. In addition, the specification and Abstract have been amended throughout to provided the correct format for reference to a sequence identifier.

Applicants also note that SEQ ID NO:44 was amended to correct the typographical error shown as a space on line 240 (page 129 of the published PCT specification), at position 181, by adding the appropriate missing nucleotide "T" at position 240 of SEQ ID NO:44. This amendment does not add new matter in as much as SEQ ID NO:44 represents the ORF encoded by the cDNA insert of clone HP10299 which corresponds to SEQ ID NO:69 at positions 93 to 440. (*See*, for example, at page 54, lines 2-7 of the published PCT application.) Comparison of SEQ ID NO:44 with SEQ ID NO:69 indicates that the missing base corresponds to T at position 332 of SEQ ID NO:69, which is the third letter of the codon of Asp-80.


Applicants submit that initial computer-readable form (diskette) of the substitute Sequence Listing is identical in substance to the paper (hard) copy of the substitute Sequence Listing, pages 92-183. Applicants further submit that the initial computer readable form of the Sequence Listing contained on the enclosed diskette and the hard copy of the substitute Sequence Listing comply with the requirements of 37 C.F.R. §§1.821 and 1.825. No new matter has been added.

CONCLUSION

If a telephone conversation with Applicants' attorney would expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' attorney at (617) 227-7400. Please charge any fees required for consideration and entry of this Amendment and Response, or credit any overpayment to Deposit Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

A handwritten signature in cursive script, appearing to read "Peter C. Lauro", is written over a horizontal line.

Peter C. Lauro, Esq.
Registration No. 32,360
Attorney for Applicants

28 State Street
Boston, MA 02109
Tel. (617) 227-7400

Dated: **June 26, 2000**

Enclosures:

Diskette containing CRF of corrected Sequence Listing;
Hard copy of corrected Sequence Listing (substitute specification pages 92-183); and
Five-month Extension of Time.